Tuesday, 17 November 2026 X LinkedIn Bluesky RSS Send us news
LungDaily The Pulse of Respiratory Health
World COPD Day is on Wednesday 18 November · #WorldCOPDDay Our coverage →
New Paper Alert

ATS 2026 guideline covers as-needed inhaled corticosteroids in asthma

Guideline Central said the American Thoracic Society guideline highlights key recommendations on two reliever strategies combining inhaled corticosteroids with either a short-acting beta2-agonist or formoterol.

“highlighting key recommendations across inhaled corticosteroid–short-acting beta2-agonist and inhaled corticosteroid–formoterol reliever strategies”— Guideline Central

Guideline Central, which describes itself as providing healthcare professionals with evidence-based clinical decision support tools and current guidelines, has drawn attention to a 2026 American Thoracic Society (ATS) guideline on as-needed inhaled corticosteroids in asthma.

In a post on X on 14 November 2026, the account said the guideline highlights key recommendations across two reliever strategies: inhaled corticosteroid–short-acting beta2-agonist and inhaled corticosteroid–formoterol.

The post does not set out the individual recommendations, their strength or the evidence behind them. It includes a link to further material. According to its profile, Guideline Central is partnered with 45 or more medical associations.

Original source

#asthma#guidelines#therapeutics

Related stories

More in New Paper Alert

See all

LungDaily reports on public posts, papers and news from the lung health community. This article is based on the source linked above and was produced with AI-assisted tools under our editorial standards; facts and quotes are checked against the original before publication. Featured here, or spotted an error? Request a correction or removal.